A detailed history of J.Safra Asset Management Corp transactions in Veracyte, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 111 shares of VCYT stock, worth $4,367. This represents 0.0% of its overall portfolio holdings.

Number of Shares
111
Previous 18 516.67%
Holding current value
$4,367
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 29, 2025

BUY
$23.03 - $34.33 $2,141 - $3,192
93 Added 516.67%
111 $3,000
Q2 2025

Oct 29, 2025

BUY
$26.39 - $32.62 $1,557 - $1,924
59 Added 113.46%
111 $3,000
Q2 2025

Jul 28, 2025

BUY
$26.39 - $32.62 $263 - $326
10 Added 125.0%
18 $0
Q1 2025

Oct 29, 2025

SELL
$29.65 - $46.14 $1,749 - $2,722
-59 Reduced 53.15%
52 $1,000
Q1 2025

Apr 25, 2025

BUY
$29.65 - $46.14 $237 - $369
8 New
8 $0

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.82B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track J.Safra Asset Management Corp Portfolio

Follow J.Safra Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J.Safra Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on J.Safra Asset Management Corp with notifications on news.